NCT05839418 Sustained Effort Network for Treatment of Status Epilepticus/European Academy of Neurology Registry on Refractory Status Epilepticus (SENSE-II/AROUSE)
| NCT ID | NCT05839418 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasme University Hospital |
| Condition | Status Epilepticus |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2023-03-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults admitted fir SE treatment in each of the participating centers and to identify predictors of outcome and refractoriness.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or above * Patients admitted for management of Status Epilepticus as their primary diagnosis * Patients admitted for another primary diagnosis but identified with Status Epilepticus during their acute hospital stay Exclusion Criteria: \- Patients with post-cardiac arrest SE
Contact & Investigator
Nicolas Gaspard, MD, PhD
PRINCIPAL INVESTIGATOR
Erasme UH
Frequently Asked Questions
Who can join the NCT05839418 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Status Epilepticus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05839418 currently recruiting?
Yes, NCT05839418 is actively recruiting participants. Contact the research team at Nicolas.Gaspard@erasme.ulb.ac.be for enrollment information.
Where is the NCT05839418 trial being conducted?
This trial is being conducted at Linz, Austria, Salzburg, Austria, Brussels, Belgium, Odense, Denmark and 7 additional locations.
Who is sponsoring the NCT05839418 clinical trial?
NCT05839418 is sponsored by Erasme University Hospital. The principal investigator is Nicolas Gaspard, MD, PhD at Erasme UH. The trial plans to enroll 3,000 participants.